Genmab launches “AI Everywhere”

Source: OpenAI Date: 2024-09-19 URL: https://openai.com/index/genmab

Summary

Summary

Genmab, a Danish biopharmaceutical company specializing in antibody therapeutics, launched an “AI Everywhere” initiative using ChatGPT Enterprise — deploying AI tools across research, clinical development, and business operations organization-wide. The initiative represented a broad internal AI adoption strategy rather than a point solution.

Implications

Healthcare/enterprise thread. “AI Everywhere” as a strategic frame signals a shift from AI pilots to AI as organizational infrastructure. Pharmaceutical companies are particularly interesting enterprise AI adopters because their core workflows (drug discovery, clinical data analysis, regulatory documentation) are knowledge-intensive and high-stakes, making AI both high-value and high-risk to deploy. Genmab’s antibody specialization means the relevant AI applications include literature synthesis, sequence analysis, and clinical trial data interpretation — domains where GPT-4-class models had demonstrated genuine utility. The organizational framing (enterprise-wide deployment vs. specific tool adoption) is a leading indicator of where enterprise AI strategy was heading in late 2024.